<DOC>
	<DOCNO>NCT00274014</DOCNO>
	<brief_summary>The objective study evaluate effect one-year treatment inhale tiotropium bromide 18 mcg daily lung function , incidence severity exacerbation patient chronic obstructive pulmonary disease ( COPD ) . The secondary purpose explore possible relationship lung function change occurrence COPD exacerbation try characterize exacerbation .</brief_summary>
	<brief_title>Measure Long Term Influence SPIRIVAÂ® Acute Respiratory Disorders</brief_title>
	<detailed_description>This multicentre , randomise , double blind , parallel group , placebo-controlled , one year study . It design determine effect inhale tiotropium treatment airflow obstruction ( PEFR ) , incidence severity exacerbation patient COPD . Following initial 3-week screening period qualify patient randomize either tiotropium placebo Visit 2 . Patients return clinic week 6 ( Visit 3 ) , 12 ( Visit 4 ) , 24 ( Visit 5 ) , 36 ( Visit 6 ) , 48 ( Visit 7 ) Week 50 conclusion trial ( Visit 8 ) . The patient receive treatment daily 48 week ( 336 day ) . PEFR , well use rescue medication respiratory condition , self-assessed patient record every morning graphical diary card every morning . The graphical presentation data suppose help investigator detect exacerbation occur two consecutive visit . Details hospitalization due COPD exacerbation record special hospitalization booklet . Study Hypothesis : The objective study evaluate effect one-year treatment inhale tiotropium bromide 18 mcg daily lung function , incidence severity exacerbation patient chronic obstructive pulmonary disease ( COPD ) . The secondary purpose explore possible relationship lung function change occurrence COPD exacerbation try characterize exacerbation . Comparison ( ) : Tiotropium 18 mcg daily v Placebo</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Diagnosis COPD accord European Respiratory Society ( ERS ) ( R953225 ) match follow criterion : Stable moderate severe airway obstruction Baseline 30 % &lt; FEV1 &lt; 65 % European Community Coal Steel ( ECCS ) predict value ( R941408 ) . Baseline FEV1/SVC &lt; 70 % . Smoking history &gt; 10 packyears ( p.y. ) . A p.y . define equivalent smoke One pack cigarettes per day one year . History exacerbation past year .</criteria>
	<gender>All</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>